Lancet Commission Highlights Global Inequality in Cancer Genetic Testing

Access to cancer genetic testing and targeted treatments is significantly unequal worldwide, according to a new Lancet Oncology commission.

Only 2% of biomarker-based cancer trials are conducted in low- and middle-income countries, compared to 81% in high-income nations.

The commission proposes a framework for prioritizing molecular tests and therapies to improve equitable integration into cancer control.